Clinical trial
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and…
NCT00069160 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00069160 |
|---|---|
| Title | Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer |
| Official title | A Clinical Trial of the P-Glycoprotein Antagonist, Tariquidar (XR9576), in Combination With Docetaxel in Patients With Lung, Ovarian, Renal and Cervical Cancer: Analysis of the Interaction Between Tariquidar and Docetaxel |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms |
| Intervention type | Drug, Other |
| Interventions | docetaxel, tariquidar, 99mTc-sestamibi imaging |
| Enrollment | 48 |
| Start date | Sep 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 16, 2003 |
| Last update posted | Oct 12, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: